Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)

Radiopharm Theranostics Limited (NASDAQ:RADX) is among the 12 Best Australian Stocks to Buy Right Now. The company recently announced receiving Investigational New Drug (IND) approval from the FDA to begin a Phase 1 therapeutic clinical study to target B7H3 with Betabart (RV-01).

Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)

A well-stocked pharmacy shelf full of the company’s pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products.

The Lu-177-B7H3 monoclonal antibody is the first in class targeted radiopharmaceutical that is being developed against the 4lg type of B7H3. Radiopharm Theranostics Limited (NASDAQ:RADX) believes it has the potential to become a highly differentiated drug for treating individuals with aggressive solid tumors. The company says it is on track to initiate the first-in-human study during the fourth quarter of this calendar year.

Findings from recent preclinical studies have shown that RV-01 exhibits hepatic clearance, which allows the isotope enough time to target tumors, while also potentially reducing adverse effects such as hematological toxicities. Moreover, these monoclonal antibodies are cleared by the liver, unlike peptides and small molecules. This, coupled with the shortened half-life of RV-01, makes this agent stand out compared to other monoclonal antibodies and targeted radiotherapeutics with a renal excretion pathway.

Radiopharm Theranostics Limited (NASDAQ:RADX) is an Australia-based clinical-stage radiotherapeutics firm developing innovative radiopharmaceutical products for therapeutic and diagnostic applications in areas of high unmet medical need.

While we acknowledge the risk and potential of RADX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RADX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now.

Disclosure: None.